Boston Scientific Corporation (NYSE:BSX) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 30, ...
NEW ALBANY — Baptist Health Floyd recently completed its 500th Watchman procedure. The Watchman device is an alternative to ...
A new Watchman device at McLaren Port Huron offers eligible AFib patients an alternative to long‑term blood thinners to help ...
Boston Scientific (BSX) stock tumbled 9% to two-year lows after Watchman trial data revealed stroke concerns and Raymond ...
CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...
Data for Boston Scientific’s Watchman FLX implant met the primary endpoint in a new study. The stock is falling anyway.
Investor's Business Daily on MSN
Boston Scientific just took a 9% header. Why analysts are still bullish
Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.
In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...
Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.
At first glance, CHAMPION-AF gives some redemption to LAA occluders after CLOSURE-AF, a smaller randomized trial that failed to show that LAA closure (using various devices) was non-inferior to NOAC ...
CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.
Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results